Download pdf
Application of CRISPR/Cas9 gene-editing technology in Alzheimer’s disease
- 1 School of Life Science and Technology, Southeast University, Nanjing, China
* Author to whom correspondence should be addressed.
Abstract
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder. It triggers metabolic disorders within the body due to genetic mutations, thus leading to irreversible damage to one's memory and brain. The primary pathogenic features of AD are intracellular neurofibrillary tangles caused by hyperphosphorylated Tau and extracellular amyloid plaques created by the buildup of β-amyloid β-protein (Aβ). However, up to now, there has been no effective treatment program for Alzheimer's disease. And after a long time of development, many gene editing technologies have been perfected and utilized in practice. Among them, CRISPR-Cas9 technology is the most efficient and practical. As a result, an increasing number of scientists have examined and debated the potential use of CRISPR-Cas9 technology in the management of Alzheimer's disease. This review addresses the use of the CRISPR/Cas9 system to treat Alzheimer's disease and presents the disease's pathophysiology, including the establishment of AD models, genetic screening for the cause of AD, and targeted therapy for AD.
Keywords
Gene-editing technology, Alzheimer’s disease (AD), CRISPR/Cas9
[1]. Liang Zhi, Fan Linlin, Li Hongliang, et al. Current status and new progress of drug treatment of Alzheimer's disease [J]. Southwest Defense Medicine,2018,28(01):85-87.
[2]. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337(6096):816-821.
[3]. Lu L, Yu X, Cai Y, Sun M, Yang H. Application of CRISPR/Cas9 in Alzheimer's Disease
[4]. Giau VV, Lee H, Shim KH, Bagyinszky E, An SSA. Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer's disease. Clinical Interventions in Aging. 2018;13:221-233.
[5]. Zhu Junyan, Chen Xiaoshan, Guo Yanxiang, et al. Experimental study on the effect of sesamin on the expression β of amyloid and β amyloid precursor protein lyase-1 in murine pheochromocytoma cells under hypoxic conditions [J]. Shaanxi Medical Journal, 2021, 50(10):1210-1213.
[6]. Nagata, K., Takahashi, M., Matsuba, Y., Okuyama-Uchimura, F., Sato, K., Hashimoto, S., Saito, T., & Saido, T. C. (2018). Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. Nature Communications, 9(1), 1800.
[7]. HE Jing, WANG Rong. Application of CRISPR/Cas9 gene editing technology in the research of Alzheimer's disease [J]. Neurological Disorders and Mental Health,2022,22(11):786-792.
[8]. Yao Liwei, Liu Meng, Chen Shuyun, et al.APOE-TREM2-mediated anti-inflammatory mechanism of osthole in an in vitro cell model of Alzheimer's disease [J]. New Drugs and Clinical Pharmacology of Traditional Chinese Medicine, 2021, 32(11):1607-1614.
[9]. Rahimi A, Sameei P, Mousavi S, Ghaderi K, Hassani A, Hassani S, Alipour S. Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases. Mol Neurobiol. 2024 Jul 17.
[10]. TAO Pengfei, Sun Yaxuan, Zhao Zhuo, et al.Research progress of CRISPR/Cas genome editing technology and its application in neurodegenerative diseases [J]. Life Sciences, 2018, 30(03):333-341.
[11]. Barman NC, Khan MM, Islam M, Nain Z, Roy RK, Haque MA, Barman SK. CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease—A Narrative Review. Neurol Ther. 2020;9(2):419-434.
Cite this article
Zhang,X. (2024). Application of CRISPR/Cas9 gene-editing technology in Alzheimer’s disease. Theoretical and Natural Science,54,63-68.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Workshop on Intelligent Medical Data Analysis for Precision Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).